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Abstract
Inflammation induced by infectious and noninfectious triggers in the kidney may lead to end stage renal disease (ESRD).
Toll-like receptor 9 (TLR-9) a receptor for CpG DNA is involved in activation of immune cells in renal disease and may
contribute to chronic inflammatory disease progression through an interleukin-6 (IL-6) dependent pathway. Previous
studies indicate that -1237T/C confers regulatory effects on TLR-9 transcription. To date the effect of TLR-9 polymorphisms
on ESRD remains unknown. We performed a case-control study and genotyped 630 ESRD patients and 415 controls for -
1237T/C, -1486T/C and 1635G/A by real-time PCR assays and assessed plasma concentration of IL-6 by ELISA. Haplotype
association analysis was performed using the Haploview package. A luciferase reporter assay and real-time PCR were used
to test the function of the -1237T/C promoter polymorphism. A significant association between -1237T/C in TLR-9 and ESRD
was identified. The TCA, TTA and CCA haplotype of TLR-9 were associated with ESRD. ESRD patients carrying -1237TC had a
higher mean plasma IL-6 level when compared with -1237TT. The TLR-9 transcriptional activity of the variant -1237CC allele
is higher than the -1237TT allele. The results indicate that in a Han Chinese population the presence of the C allele of -
1237T/C in the TLR-9 gene increases susceptibility towards development of ESRD. In vitro studies demonstrate that -1237T/
C may be involved in the development of ESRD through transcriptional modulation of TLR-9.
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Introduction
In Taiwan chronic kidney disease (CKD) is a major public
health problem due to its high prevalence, high rates of healthcare
utilization, high risk of progression to end-stage renal disease
(ESRD) and poor prognosis [1]. The rising tide of CKD not only
adds burden to global health-care resources but also has major
impact on patients and their families. CKD is classified as a
multifactorial disease as a combination of genetic and environ-
mental factors influence the onset and development of ESRD
[2,3]. It is now recognized that inflammation may be established
before the onset of renal disease and could be a causal factor in the
development of CKD. Sensors of the innate immune system,
including Toll-like receptors (TLRs), provide danger recognition
platforms on immune and renal cells. These can integrate and
translate the diverse triggers of renal inflammation by regulating
cell activation and production of proinflammatory cytokines and
chemokines [4–6].
Mammalian TLRs comprise a large family of at least 11
members. Members of the TLR family play an important role in
both innate and adaptive immune responses. Their genes have
been found to be polymorphic [7]. TLRs recognize a wide variety
of pathogen associated molecular patterns (PAMPs) from bacteria,
viruses and fungi as well as some host molecules. TLR-9, expressed
within the endosomal compartment, recognizes unmethylated
CpG motifs present in bacterial DNA and intracellular viral
antigens [8]. Recent studies have suggested roles for TLR-9 in the
development of renal diseases such as glomerulonephritis [9] and
lupus nephritis [10]. Single nucleotide polymorphisms (SNPs) in
TLR genes affect the susceptibility to and severity of inflammatory
diseases by influencing the function of these receptors. The profile
of currently known genetic polymorphisms in TLR-9 has been
proposed to associate with severe clinical phenotypes [11,12] and
TLR-9 polymorphisms appear to affect IgA nephropathy
progression [13].
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In a human embryonic kidney cell line (HEK293) model system
the ability to respond to physiological and therapeutic TLR-9
ligands depends on TLR-9 SNPs [14]. -1237T/C confers
regulatory effects on TLR-9 transcription [15]. Indeed the C
allele of the -1237T/C polymorphism generates several regulatory
sites, including an IL-6-responsive element [16] and was associated
with chronic renal disease in a limited candidate gene study [17].
The affect of TLR-9 polymorphisms on ESRD however remains
unknown. Therefore we investigated the predictive value of TLR-
9 gene polymorphisms on ESRD in a Han Chinese population
and undertook in vitro experiments to study potential mechanisms
of any associations.
Methods
Study Subjects
This case-control study included 630 ESRD patients (325
females and 305 males; age 64.62614.51 years) recruited from the
Cardinal Tien Hospital and five hemodialysis centers in Taipei,
Taiwan. CKD was defined according to KDOQI (Kidney Disease
Outcomes Quality Initiative) definitions and estimated glomerular
filtration rate (eGFR) was calculated using the Modification of
Diet in Renal Disease (MDRD) Study equation [18]. ESRD was
defined as eGFR ,15 ml/min/1.73 m2 associated with clinical
signs of uremic syndrome requiring dialysis. The enrolled patients
were stable (without clinical complications), aged over 20 and had
been on hemodialysis (HD) for more than 6 months. Patients with
autoimmune disease, malignancy and acute or chronic infection
were excluded. The causes of ESRD were diabetes mellitus in 244
patients (38.7%), chronic glomerulonephritis in 199 patients
(31.6%), hypertensive nephropathy in 76 patients (12.1%),
systemic nephropathy in 51 patients (8.1%) and other and
unknown causes in 60 patients (9.5%). The 415 healthy control
subjects (217 females and 198 males; age 74.9167.50 years) with
no history of renal disease and whose eGFR was $60 ml/min/
1.73 m2 were recruited from the Center of Physical Examination
at Cardinal Tien Hospital. The healthy control subjects showed no
microalbuminuria, proteinuria or hematuria and had normal
abdominal/renal ultrasonography. 24.5% healthy controls report-
ed a history for hypertension and 13.3% for diabetes mellitus.
Ethics Statement
The study was reviewed and approved by the institutional
ethical committee of Cardinal Tien Hospital (CTH-98-3-5-045).
After full explanation of the study written informed consent was
obtained from all participants. All clinical and biological samples
were collected and DNA was genotyped following patient consent.
SNP Genotyping
Genomic DNA was extracted from the peripheral blood of
patients and controls using the QIAamp DNA Blood Mini Kit
(QIAGEN Inc., Hilden, Germany) according to the manufactur-
er’s instructions. Genotyping for the TLR-9 -1237T/C
(rs5743836), -1486T/C (rs187084) and -1635G/A (rs352140)
was performed by real-time polymerase chain reaction (PCR).
Genotypes were determined using the LightCycler 1.2 System
(Roche Diagnostics, Salt Lake City, UT, USA). Primer and
detection probes for each polymorphism were based on Hamann
et al. and Soriano-Sarabia et al. [19,20]. Melting curve analyses
for TLR genes were performed using 2.5 mM of each detection
probe. After an initial denaturation at 95uC for 10 minutes at a
ramp rate of 4.4uC/s, temperature was dropped to 45uC at a ramp
rate of 1uC/s and finally led to 80uC with one acquisition per
degree Celsius. Genotyping was done by laboratory personnel
blinded to case status and a random 10% of the samples were
repeated to validate genotyping procedures.
Peripheral blood mononuclear cell Culture and Plasma
Interleukin-6 Concentration
Peripheral blood mononuclear cells (PBMCs) were prepared
from venous blood by Ficoll-Hypaque density-gradient centrifu-
gation (Amersham Pharmacia Biotech, Little Chalfont, UK).
PBMCs were plated at a density of 16106 cells/ml in 12-well cell
culture plates with RPMI 1640 supplemented with 10% heat-
inactivated fetal calf serum (FCS) and 100 mg/ml streptomycin.
Plasma concentration of interleukin-6 (IL-6) was determined by
ELISA using human Quantikine ELISA kit (R&D Systems,
Minneapolis, MN, USA).
Expression Analysis by Real-time Quantitative Reverse
Transcription Polymerase Chain Reaction
16106 PBMCs cultured as above were serum starved and
treated with 100 pg/ml IL-6 for 24 hours. Total RNA was isolated
using TriZOL reagent (Invitrogen Cor., Carlsbad, CA, USA).
Two microgram of total RNA was reverse transcribed by use of
the High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA, USA) into cDNA. Real-time PCR
was performed with the MaximaH SYBR green qPCR master mix
(Fermentas, Glen Burnie, MD, USA), using an ABI 7500 real-time
PCR system (Applied Biosystems). Primer sequences were as
follows: TLR-9 forward 59-CCCGCTACTGGTGCTATCC-39
and reverse 59-CCTTCCTCTTTCCACTCCC-39; b-actin for-
ward 59-AGTTGCGTTACACCCTTTCTTG-39 and reverse 59-
TCACCTTCACCGTTCCAGTTT-39. Thermocycling was per-
formed at 95uC for 10 min, 40 cycles of 95uC for 15 s and 60uC
for 60 s to measure the fluorescence signal. The dissociation
stages, melting curves and quantitative analyses of the data were
performed using 7500 system software v1.2.3 (Applied Biosystems).
Expression of b-actin was used as internal control. TLR-9 gene
expression normalized by b-actin was calculated by using the
22DDCt method.
Transient Transfection and Luciferase Assay
Two TLR-9 promoter reporters (from 52260706 to 52260840,
135 bp), TLR-9-1237TT-LUC and TLR-9-1237CC-LUC, were
amplified by PCR from human genomic DNA including the SNP
of interest (-1237T/C) and subcloned into a pGL3 basal reporter
cut at XhoI and HindIII sites. The 59 and 39 primers used for PCR
were: 59- CCgCTCgAgATGGGAGCAGAGACATAATGGA-39
and 59-CCCAAgCTTCTGCTTGCAGTTGACTGTGT-39.
HEK293 cells were grown in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% charcoal/dextran-treated fetal
bovine serum. The cells in each well (24-well plate) were
transfected with jetPEI (PolyPlus-transfection, Illkirch, France)
according to the manufacturer’s protocol; total DNA was adjusted
to 1.0 mg by addition of the pGL3 reporter. 24 hours post
transfection HEK293 cells were treated with IL-6 (5 ng/ml) for an
additional 18 hours. Luciferase activity was assessed using the
Promega Luciferase Assay kit and expressed as mean relative light
units (RLU) of two transfected sets. Results shown are represen-
tative of at least three independent experiments.
Statistical Analysis
Statistical analysis was performed with SPSS for windows
version 18.0 (SPSS, Chicago, IL, USA). Demographic, clinical
data and plasma IL-6 concentration between groups were
compared by Student’s t test or Mann-Whitney U test. The
The Functional TLR-9 Promoter Polymorphism in ESRD
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results for continuous variables are given as means 6 SD. The
genotype distributions were tested for Hardy-Weinberg equilibri-
um. The comparison of the allele and genotype frequencies
between the different groups was evaluated by Chi-square test or
Fisher’s exact test when appropriate. The odds ratios (ORs) and
corresponding 95% confidence intervals (CIs) for assessing the
effect of the genotype distribution and allele frequencies on ESRD
were calculated by logistic regression analysis with adjustment for
relevant significant variables. Statistical significance was defined at
the 95% level (P,0.05). Linkage disequilibrium (LD) and
haplotype analyses were performed using Haploview software
[21] (http://www.broad.mit.edu/mpg/haploview/) and WHAP
(http://pngu.mgh.harvard.edu/,purcell/whap/), respectively.
Associations of TLR-9 promoter polymorphism with TLR-9
mRNA expression were assessed by the Kruskal-Wallis (K-W) test.
Results
Demographic Characteristics
The characteristics of the 1,045 subjects are presented in
Table 1. There was no significant difference in gender and
diastolic blood pressure between the two groups. Significant
differences in age, BMI, smoking history, systolic blood pressure,
fasting blood sugar, eGFR, BUN, serum creatinine, total
cholesterol and triglycerides were observed between ESRD
patients and controls (P,0.001).
Association Analyses of TLR-9 Gene Polymorphisms with
Susceptibility to ESRD
The distributions of TLR-9 -1237T/C, -1486T/C and 1635G/
A genotypes and allele frequencies were compared between ESRD
patients and controls (Table 2). The genotypic distributions of the
gene polymorphisms in the patients and controls fit the Hardy-
Weinberg equilibrium. The genotype and allelic distributions of -
1237T/C in TLR-9 was significantly different between the
patients and healthy controls (adjusted OR = 4.49, 95%
CI = 1.75–11.49, P = 0.002 and adjusted OR = 4.36, 95%
CI = 1.72–11.08, P = 0.002, respectively). There were no signifi-
cant differences of genotypic and allelic frequencies in either the
TLR-9 -1486T/C or 1635G/A between ESRD patients and
controls. The dominant genetic models showed that -1486T/C
may be a protective factor for ESRD (adjusted OR = 0.71, 95%
CI = 0.53–0.97, P = 0.03).
Although a higher eGFR was observed for patients with the
TLR-9 -1237TT genotype this did not reach statistical significance
and overall there was no significant association between TLR-9 -
1237T/C and the degree of renal function in the ESRD group
(results not shown). Stratifying patients by the underlying cause of
their renal disease demonstrated marginal associations with
genotype and both glomerulonephritis (p= 0.04) and hypertension
(P = 0.03) but not with diabetic (P = 0.08) or systemic nephropathy
(P = 0.13) (results not shown).
Haplotype Analysis of TLR-9
The haplotype analysis of TLR-9 polymorphisms in ESRD
patients and control subjects is shown in Table 3. The frequency of
haplotype ‘‘TCA’’ was 27.8% in the ESRD patients compared to
34.6% in the controls (OR = 0.73, 95% CI = 0.60–0.88,
P = 0.001). In contrast haplotypes TTA and CCA were more
common in ESRD patients (6.5% and 2.5%, respectively) than in
controls (1.9% and 0.6%, respectively) (OR = 3.47 and 4.45, 95%
CI = 2.02–5.97 and 1.70–11.67, P,0.001 and ,0.001, respec-
tively). Other haplotypes showed no significant difference (Table 3).
Association of TLR-9 -1237 T/C Polymorphism with
Plasma IL-6 Level
We evaluated whether the TLR-9 -1237 T/C polymorphism
might be associated with IL-6 levels in the plasma of ESRD
patients. Data are shown in figure 1. Compared to healthy controls
(1.5660.24 pg/ml) the ESRD patients (4.5460.38 pg/ml) showed
a significantly higher level of plasma IL-6 (P,0.001, figure 1A).
The plasma IL-6 level did not differ significantly in healthy
controls between different TLR-9 -1237T/C genotypes (TT:
1.5560.10 pg/ml; TC: 1.6060.11 pg/ml, P = 0.87, figure 1B).
The ESRD patients carrying -1237TC had a higher mean plasma
IL-6 level (5.4760.56 pg/ml) when compared with -1237TT
(3.7160.40 pg/ml; P = 0.01, figure 1C). No significant association
was shown for other TLR-9 polymorphisms with plasma IL-6
concentration (results not shown).
TLR-9 mRNA Expression in PBMCs
The results of TLR-9 gene expression among 32 ESRD patients
are shown in figure 2. Under basal conditions and following IL-6
treatment there was no significant difference in the expression of
TLR-9 mRNA between the TT (n = 18) and TC (n = 14)
genotypes (basal condition, TT = 1.0960.09, TC = 1.2160.25;
IL-6 treatment, TT = 1.0460.08, TC = 1.0860.21. mean 6 SEM
relative mRNA expression). Similar results were seen in samples
from healthy controls (TT = 8, TC = 7) (results not shown). Under
basal conditions or following IL-6 treatment there was no
significant difference in the expression of TLR-9 mRNA between
the genotypes (mean 6 SEM relative mRNA expression: basal
condition, TT = 1.1260.15, TC = 1.1960.18; IL-6 treatment:
TT = 1.0860.19, TC = 1.1660.21).
Comparison of Promoter Activity of TT and CC Alleles of
the TLR-9 Promoter -1237T/C
To establish whether the TLR-9 SNPs were functionally
important we investigated whether IL-6 influenced TLR-9
Table 1. Clinical and biochemical parameters in ESRD
patients and control subjects.
Patients
n=630
Controls
n =415 P value
Male (%) 48.4 47.6 0.80
Age (yrs) 64.62614.51 74.9167.50 ,0.001
Body mass index (kg/m2) 21.7165.39 24.1863.11 ,0.001
Current or former smoker (%) 22.8 14.0 ,0.001
Systolic blood pressure
(mmHg)
140.86633.25 129.14615.64 ,0.001
Diastolic blood pressure
(mmHg)
75.39610.84 75.14611.96 0.72
Fasting plasma glucose
(mg/dL)
143.76656.94 102.56622.59 ,0.001
eGFR 7.8168.33 84.67616.90 ,0.001
BUN (mg/dL) 65.53619.10 16.2766.22 ,0.001
Serum creatinine (mg/dL) 9.4062.60 0.8660.32 ,0.001
Serum total cholesterol
(mg/dL)
166.49633.38 187.44632.98 ,0.001
Serum triglycerides (mg/dL) 152.33695.92 116.50658.55 ,0.001
Quantitative data are mean 6 SD.
doi:10.1371/journal.pone.0058444.t001
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promoter activity using a luciferase reporter assay in HEK293
cells. The results are shown in figure 3. The luciferase activity of
the C allele was significantly higher in the absence (10.5061.06)
and presence of IL-6 (11.1560.16) in comparison to that of the T
allele (basal condition 5.6160.29 and following IL-6 treatment
6.6160.12) (P = 0.01). However there was no significant difference
in TLR-9 promoter activity between -1237TT and -1237TC
following IL-6 treatment (P = 0. 10 and 0.49, respectively).
Discussion
Based on a previous study by our group [17] we have examined
possible associations between three TLR-9 SNPs and ESRD in a
Han Chinese population. Furthermore, in view of the known
interactions between TLR-9 and IL-6 we also studied the
association between TLR-9 -1237T/C and plasma IL-6 levels in
ESRD and performed functional studies using this SNP. Our study
has shown a statistically significant association between a
polymorphism in the promoter of TLR-9 gene (-1237T/C) and
ESRD. A weaker association between TLR-9 -1486T/C and
ESRD was seen in dominant genetic models. The study groups
were matched for sex but there were significant differences in
BMI, smoking status and age between ESRD patients and healthy
controls. Indeed it is recognized that patients with ESRD are often
malnourished [22,23] and malnourishment is associated with poor
survival in these patients [24]. We have used a non-matched case-
control design and applied multiple logistic regression to adjust for
confounders. Interestingly a study analyzing the quality of life of
irritable bowel syndrome patients compared results when groups
were matched and non-matched and found identical results.
Indeed the matching procedure slightly diminished the statistical
power of the results [25]. In the current study the frequency of
TLR9 -1237T/C was 1%. The allele frequency of this SNP in the
Han Chinese population (0.007–0.03) [17,26,27] is significantly
different from Caucasians (0.10–0.15) and African Americans
Table 2. Genotype distributions and allele frequencies for the TLR-9 gene in ESRD patients and control subjects.
Genotypes Patients n or (%) Controls n or (%) Crude OR (95% CI) P value *Adjusted OR (95% CI) P value
T-1237C ,0.001
TT 591 408 1 1
TC 39 7 3.85 (1.70–8.68) 0.001 4.49 (1.75–11.49) 0.002
Alleles
T-allele 97% 99% 1 1
C-allele 3% 1% 3.76 (1.67–8.44) 0.001 4.36 (1.72–11.08) 0.002
T-1486C 0.10
TT 276 155 1 1
TC 290 208 0.78 (0.60–1.02) 0.07 0.72 (0.52–1.00) 0.05
CC 64 52 0.69 (0.46–1.05) 0.08 0.68 (0.41–1.13) 0.14
Alleles
T-allele 67% 62% 1 1
C-allele 33% 38% 0.82 (0.69–0.99) 0.04 0.80 (0.64–1.00) 0.05
#D model 276/354 155/260 0.77 (0.59–0.99) 0.04 0.71 (0.53–0.97) 0.03
&R model 566/64 363/52 0.79 (0.54–1.17) 0.23 0.81 (0.51–1.30) 0.39
G1635A 0.90
GG 245 158 1 1
GA 306 206 0.96 (0.73–1.25) 0.75 0.94 (0.68–1.30) 0.72
AA 79 51 1.00 (0.67–1.50) 0.99 0.97 (0.59–1.58) 0.90
Alleles
G-allele 63% 63% 1 1
A-allele 37% 37% 0.99 (0.82–1.19) 0.90 0.97 (0.78–1.21) 0.81
#D model 245/385 158/257 0.97 (0.75–1.25) 0.79 0.95 (0.70–1.29) 0.73
&R model 551/79 364/51 1.02 (0.70–1.49) 0.90 1.00 (0.63–1.58) 0.99
*Data are expressed as n or (%) and have been adjusted by gender, age, BMI, and smoking status.
#D model =Dominant model.
&R model = Recessive model.
doi:10.1371/journal.pone.0058444.t002
Table 3. Haplotype frequencies in TLR-9 of ESRD patients and
control subjects.
Haplotype Frequencies
T-1237C T-1486C G1635A Patients Controls P value OR (95% CI)
T T G 0.603 0.603 0.90 1.00 (0.83–1.19)
T C A 0.278 0.346 0.001 0.73 (0.60–0.88)
T T A 0.065 0.019 ,0.001 3.47 (2.02–5.97)
T C G 0.023 0.023 0.90 1.02 (0.57–1.83)
C C A 0.025 0.006 ,0.001 4.45 (1.70–11.67)
doi:10.1371/journal.pone.0058444.t003
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(0.25–0.39) [28,29]. This indicates the existence of a geographic/
ethnic-specific difference in TLR-9 genotypes that may in part
reflect ethnic diversity to ESRD susceptibility or other conditions
where TLR-9 pathways may be involved.
There is emerging evidence that TLR-9 may play an important
role in renal disease and a number of inflammatory conditions of
other organ systems. Activation of TLR-9 induces progression of
renal disease in MRL-Fas (lpr) mice [30]. TLR-9 has been shown
to be involved in antigen-induced immune complex glomerulone-
phritis and lupus nephritis through regulation of both humoral and
cellular immune responses [31]. With respect to TLR-9 SNPs, the
-1237T/C polymorphism has been shown to be associated with
asthma [29], Crohn’s disease [32] and HIV infection [33]. The
TLR-9 2848 AA genotype is associated with significantly higher
expression of TLR-9 and the frequency of intracellular IgM
positive B cells in patients with Primary Biliary Cirrhosis [34]
whilst the TLR-9 1635G/A polymorphism appears to play a role
in the susceptibility to Systemic lupus erythematosus (SLE) in a
Chinese population [35]. Less is known regarding TLR-9 SNPs
and renal disease. We have previously identified an association
between CKD and the -1237T/C of TLR-9 [17] whilst another
group has shown that +1174A/G is associated with increased risk
for progression of IgA nephropathy in Japanese patients [36] and
patients with a TT genotype at 1635G/A show more severe renal
damage and poorer therapeutic outcomes [37].
The haplotype of three polymorphisms in TLR-9 was associated
with ESRD in the current study. Our data indicate that ESRD
Figure 1. Effects of TLR-9 -1237T/C genotype on the level of
plasma IL-6 in healthy controls and ESRD patients. IL-6
concentration was quantified by ELISA. Results are expressed as mean
6 SEM. The columns represent the mean value and the lines represent
standard error of mean. A: Compared to the healthy controls, the ESRD
patients showed a significant increase in plasma IL-6 level (P,0.001). B:
The difference of mean level of IL-6 between TT (n = 22) and TC (n = 7)
carriers was not significant (P = 0.87) in healthy controls. C: The
difference of mean level of IL-6 between TT (n = 18) and TC (n = 14)
carriers showed significant difference (P = 0.01) in ESRD patients.
*P,0.05.
doi:10.1371/journal.pone.0058444.g001
Figure 2. Comparison of PBMC TLR-9 mRNA expression
between different genotypes of -1237T/C. b-actin gene expres-
sion was used as an internal control gene. TLR-9 mRNA expression in TT
or TC PBMCs in the absence or presence of IL-6 (100 pg/ml) treatment
was assessed. Values shown are mean 6 SEM. Experiments were
performed in triplicate.
doi:10.1371/journal.pone.0058444.g002
Figure 3. Effects of the -1237T/C genotype in TLR-9 promoter
on luciferase activity in cultured HEK293 cells. Luciferase
reporters containing a TLR-9 promoter sequence with the wild-type T
allele or risk C allele at SNP -1237T/C were transfected into HEK293 cells.
The mean 6 SEM is given for each construct from three experiments.
*P,0.05.
doi:10.1371/journal.pone.0058444.g003
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patients carrying the TCA haplotype had a lower risk of ESRD
than those not carrying this haplotype whilst patients carrying the
TTA or CCA haplotype had a higher risk of ESRD than those not
carrying these haplotypes. Holla et al. (2009) demonstrated
previously that the TLR-9 TTA haplotype may increase
susceptibility to chronic periodontitis whereas the TLR-9 TCG
haplotype has a protective effect against this condition [38].
Specific haplotypes in the TLR-9 gene might affect host defense
mechanisms and influence susceptibility or resistance to infections.
Common TLR-9 alleles with a frequency higher than 5% however
do not appear to contribute significantly to the genetic risk
involved in susceptibility to SLE or lupus nephritis [39]. Further
work is required to fully understand the role of TLR-9 haplotypes
on the genetic susceptibility to ESRD.
TLR-9 has been mapped to chromosome 3p21.3. It spans
approximately 5 kb and has two exons, the second of which is the
major coding region. To date several transcription factors such as
AP-1, Sp-1, NF-kB, GATA and CRE are recognized to regulate
expression of the TLR-9 gene [40]. In the current study we
assessed the functionality of the TLR-9 -1237T/C polymorphism
for effects on transcriptional activity. Our data suggest that
transcriptional activity of the variant C allele is higher than that of
the wild-type T allele. This may be a consequence of creation of an
NF-kB binding site with the C allele [41]. Indeed higher
transcriptional activity was seen in the presence of the CC allelic
variant. These results are consistent with observations of a
moderate increase in promoter activity associated with the -
1237CC genotype of TLR-9 in asthma patients [15]. Higher
promoter activity of the TT allelic variant at -1237T/C in atopic
eczema [42] may relate to different pathogenic mechanisms and
indicate the need for further investigation in this area. In silico
analysis of the human TLR-9 promoter reveals that the C allele of
the -1237T/C polymorphism generates several new regulatory
sites including an IL-6-responsive element [16]. In the study of
Carvalho et al (2011) PBMCs containing the TC allele but not
those with the TT allele increased TLR-9 gene expression in
response to IL-6 [16]. In contrast no association between -1237T/
C genotype and TLR-9 mRNA level or promoter activity
following IL-6 treatment was identified in the current study. The
reason for this discrepancy is not clear but differences in cell
sources, detection methods, and time course of experiments in
addition to the complexity of gene regulation in vivo may be
relevant.
IL-6 is a pleiotropic cytokine that plays a central role in
modulating inflammatory responses. Several studies have indicat-
ed that IL-6 is a reliable predictor of mortality in ESRD [43,44].
B-cell activation with a TLR-9 agonist significantly increases
production of IL-6 in ESRD patients when compared to normal
age-matched controls [45]. Associations between genetic poly-
morphisms and plasma IL-6 levels have been identified [46]. SNPs
in the IL-6 gene are associated with plasma IL-6 in myocardial
infarction survivors [47] and IL-6 plasma levels are modulated by
a polymorphism in the NF-kB1 gene [48]. Our data revealing that
ESRD patients carrying -1237TC in TLR-9 gene had a higher
mean plasma IL-6 level than those carrying -1237TT are
consistent with previous observations [16]. SNPs in the promoter
region affecting TLR-9 transcriptional activity might explain inter-
individual variability in the production of IL-6 in ESRD patients.
However whether a TLR-9/IL-6 signal amplification loop such as
that which regulates B cell proliferation [16] is active in patients
with renal disease remains to be investigated.
In conclusion, we found the -1237T/C SNP of the TLR-9 gene
is significantly associated with ESRD in a Han-Chinese population
and that -1237T/C may be involved in the development of ESRD
through transcriptional modulation of TLR-9. These observations
provide new insights into the role of TLR-9 polymorphisms in
renal disease that have the potential to provide new avenues for
treatment and may also allow identification of individuals at risk.
Author Contributions
Conceived and designed the experiments: HYY KCL HSL DMS SLS.
Performed the experiments: HYY KCL SMH YFL CCW. Analyzed the
data: HYY HSL SMH YFL CCW SLS. Contributed reagents/materials/
analysis tools: KCL HSL SMH YFL SLS. Wrote the paper: HYY HSL
SMH DMS SLS.
References
1. Wen CP, Cheng TY, Tsai MK, Chang YC, Chan HT, et al. (2008) All-cause
mortality attributable to chronic kidney disease: a prospective cohort study based
on 462 293 adults in Taiwan. Lancet 371: 2173–2182.
2. Satko SG, Sedor JR, Iyengar SK, Freedman BI (2007) Familial clustering of
chronic kidney disease. Semin Dial 20: 229–236.
3. Adler S (2006) Renal disease: environment, race, or genes? Ethn Dis 16: S2-35–
39.
4. Eleftheriadis T, Lawson BR (2009) Toll-like receptors and kidney diseases.
Inflamm Allergy Drug Targets 8: 191–201.
5. Smith KD (2009) Toll-like receptors in kidney disease. Curr Opin Nephrol
Hypertens 18: 189–196.
6. Koc M, Toprak A, Arikan H, Odabasi Z, Elbir Y, et al. (2011) Toll-like receptor
expression in monocytes in patients with chronic kidney disease and
haemodialysis: relation with inflammation. Nephrol Dial Transplant 26: 955–
963.
7. Schwartz DA, Cook DN (2005) Polymorphisms of the Toll-like receptors and
human disease. Clin Infect Dis 41 Suppl 7: S403–407.
8. Dalpke A, Zimmermann S, Heeg K (2002) CpG DNA in the prevention and
treatment of infections. Bio Drugs 16: 419–431.
9. Summers SA, Steinmetz OM, Ooi JD, Gan PY, O’Sullivan KM, et al. (2010)
Toll-like receptor 9 enhances nephritogenic immunity and glomerular leukocyte
recruitment, exacerbating experimental crescentic glomerulonephritis.
Am J Pathol 177: 2234–2244.
10. Summers SA, Hoi A, Steinmetz OM, O’Sullivan KM, Ooi JD, et al. (2010)
TLR9 and TLR4 are required for the development of autoimmunity and lupus
nephritis in pristane nephropathy. J Autoimmun 35: 291–298.
11. Bochud PY, Hersberger M, Taffe P, Bochud M, Stein CM, et al. (2007)
Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1
infection. AIDS 21: 441–446.
12. Krayenbuehl PA, Hersberger M, Truninger K, Mullhaupt B, Maly FE, et al.
(2010) Toll-like receptor 4 gene polymorphism modulates phenotypic expression
in patients with hereditary hemochromatosis. Eur J Gastroenterol Hepatol 22:
835–841.
13. Suzuki H, Suzuki Y, Narita I, Aizawa M, Kihara M, et al. (2008) Toll-like
receptor 9 affects severity of IgA nephropathy. J Am Soc Nephrol 19: 2384–
2395.
14. Kubarenko AV, Ranjan S, Rautanen A, Mills TC, Wong S, et al. (2010) A
naturally occurring variant in human TLR9, P99L, is associated with loss of
CpG oligonucleotide responsiveness. J Biol Chem 285: 36486–36494.
15. Lange NE, Zhou X, Lasky-Su J, Himes BE, Lazarus R, et al. (2011)
Comprehensive genetic assessment of a functional TLR9 promoter polymor-
phism: no replicable association with asthma or asthma-related phenotypes.
BMC Med Genet 12: 26.
16. Carvalho A, Osorio NS, Saraiva M, Cunha C, Almeida AJ, et al. (2011) The C
allele of rs5743836 polymorphism in the human TLR9 promoter links IL-6 and
TLR9 up-regulation and confers increased B-cell proliferation. PLoS One 6:
e28256.
17. Lu KC, Yang HY, Lin YF, Kao SY, Lai CH, et al. (2011) The T-1237C
polymorphism of the Toll-like receptor-9 gene is associated with chronic
kidney disease in a Han Chinese population. Tohoku J Exp Med 225:
109–116.
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, et al. (1999) A more
accurate method to estimate glomerular filtration rate from serum creatinine: a
new prediction equation. Modification of Diet in Renal Disease Study Group.
Ann Intern Med 130: 461–470.
19. Hamann L, Hamprecht A, Gomma A, Schumann RR (2004) Rapid and
inexpensive real-time PCR for genotyping functional polymorphisms within the
Toll-like receptor -2, -4, and -9 genes. J Immunol Methods 285: 281–291.
20. Soriano-Sarabia N, Vallejo A, Ramirez-Lorca R, Rodriguez Mdel M, Salinas A,
et al. (2008) Influence of the Toll-like receptor 9 1635A/G polymorphism on the
CD4 count, HIV viral load, and clinical progression. J Acquir Immune Defic
Syndr 49: 128–135.
The Functional TLR-9 Promoter Polymorphism in ESRD
PLOS ONE | www.plosone.org 6 March 2013 | Volume 8 | Issue 3 | e58444
21. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and
visualization of LD and haplotype maps. Bioinformatics 21: 263–265.
22. Kopple JD, Greene T, Chumlea WC, Hollinger D, Maroni BJ, et al. (2000)
Relationship between nutritional status and the glomerular filtration rate: results
from the MDRD study. Kidney Int 57: 1688–1703.
23. Gama-Axelsson T, Heimburger O, Stenvinkel P, Barany P, Lindholm B, et al.
(2012) Serum albumin as predictor of nutritional status in patients with ESRD.
Clin J Am Soc Nephrol 7: 1446–1453.
24. Jansen MA, Korevaar JC, Dekker FW, Jager KJ, Boeschoten EW, et al. (2001)
Renal function and nutritional status at the start of chronic dialysis treatment.
J Am Soc Nephrol 12: 157–163.
25. Faresjo T, Faresjo A (2010) To match or not to match in epidemiological
studies–same outcome but less power. Int J Environ Res Public Health 7: 325–
332.
26. Ng MW, Lau CS, Chan TM, Wong WH, Lau YL (2005) Polymorphisms of the
toll-like receptor 9 (TLR9) gene with systemic lupus erythematosus in Chinese.
Rheumatology (Oxford) 44: 1456–1457.
27. Wu JF, Chen CH, Ni YH, Lin YT, Chen HL, et al. (2012) Toll-like receptor and
hepatitis B virus clearance in chronic infected patients: a long-term prospective
cohort study in Taiwan. J Infect Dis 206: 662–668.
28. Velez DR, Wejse C, Stryjewski ME, Abbate E, Hulme WF, et al. (2010) Variants
in toll-like receptors 2 and 9 influence susceptibility to pulmonary tuberculosis in
Caucasians, African-Americans, and West Africans. Hum Genet 127: 65–73.
29. Lazarus R, Klimecki WT, Raby BA, Vercelli D, Palmer LJ, et al. (2003) Single-
nucleotide polymorphisms in the Toll-like receptor 9 gene (TLR9): frequencies,
pairwise linkage disequilibrium, and haplotypes in three U.S. ethnic groups and
exploratory case-control disease association studies. Genomics 81: 85–91.
30. Anders HJ, Vielhauer V, Eis V, Linde Y, Kretzler M, et al. (2004) Activation of
toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice.
FASEB J 18: 534–536.
31. Anders HJ, Banas B, Schlondorff D (2004) Signaling danger: toll-like receptors
and their potential roles in kidney disease. J Am Soc Nephrol 15: 854–867.
32. To¨ro¨k HP, Glas J, Endres I, Tonenchi L, Teshome MY, et al. (2009) Epistasis
between Toll-like receptor-9 polymorphisms and variants in NOD2 and IL23R
modulates susceptibility to Crohn’s disease. Am J Gastroenterol 104: 1723–1733.
33. Soriano-Sarabia N, Vallejo A, Ramı´rez-Lorca R, Rodrı´guez MM, Salinas A, et
al. (2008) Influence of the Toll-like receptor 9 1635A/G polymorphism on the
CD4 count, HIV viral load, and clinical progression. J Acquir Immune Defic
Syndr 49: 128–135.
34. Kikuchi K, Lian ZX, Kimura Y, Selmi C, Yang GX, et al. (2005) Genetic
polymorphisms of toll-like receptor 9 influence the immune response to CpG
and contribute to hyper-IgM in primary biliary cirrhosis. J Autoimmun 24: 347–
352.
35. Xu CJ, Zhang WH, Pan HF, Li XP, Xu JH, et al. (2009) Association study of a
single nucleotide polymorphism in the exon 2 region of toll-like receptor 9
(TLR9) gene with susceptibility to systemic lupus erythematosus among Chinese.
Mol Biol Rep 36: 2245–2248.
36. Suzuki H, Suzuki Y, Narita I, Aizawa M, Kihara M, et al. (2008) Toll-like
receptor 9 affects severity of IgA nephropathy. J Am Soc Nephrol 19: 2384–
2395.
37. Sato D, Suzuki Y, Kano T, Suzuki H, Matsuoka J, et al. (2012) Tonsillar TLR9
expression and efficacy of tonsillectomy with steroid pulse therapy in IgA
nephropathy patients. Nephrol Dial Transplant 27: 1090–1097.
38. Holla LI, Vokurka J, Hrdlickova B, Augustin P, Fassmann A (2009) Association
of Toll-like receptor 9 haplotypes with chronic periodontitis in Czech
population. J Clin Periodontol 37: 152–159.
39. De Jager PL, Richardson A, Vyse TJ, Rioux JD (2006) Genetic variation in toll-
like receptor 9 and susceptibility to systemic lupus erythematosus. Arthritis
Rheum 54: 1279–1282.
40. Takeshita F, Suzuki K, Sasaki S, Ishii N, Klinman DM, et al. (2004)
Transcriptional regulation of the human TLR9 gene. J Immunol 173: 2552–
2561.
41. Ng MT, Van’t Hof R, Crockett JC, Hope ME, Berry S, et al. (2010) Increase in
NF-kappaB binding affinity of the variant C allele of the toll-like receptor 9 -
1237T/C polymorphism is associated with Helicobacter pylori-induced gastric
disease. Infect Immun 78: 1345–1352.
42. Novak N, Yu CF, Bussmann C, Maintz L, Peng WM, et al. (2007) Putative
association of a TLR9 promoter polymorphism with atopic eczema. Allergy 62:
766–772.
43. Hasuike Y, Nonoguchi H, Ito K, Naka M, Kitamura R, et al. (2009) Interleukin-
6 is a predictor of mortality in stable hemodialysis patients. Am J Nephrol 30:
389–398.
44. Zoccali C, Tripepi G, Mallamaci F (2006) Dissecting inflammation in ESRD:
Do cytokines and C-reactive protein have a complementary prognostic value for
mortality in dialysis patients? J Am Soc Nephrol 17: S169–S173.
45. Pahl MV, Gollapudi S, Sepassi L, Gollapudi P, Elahimehr R, et al. (2010) Effect
of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and
BAFF receptor expression. Nephrol Dial Transplant 25: 205–212.
46. Smith AJ, Humphries SE (2009) Cytokine and cytokine receptor gene
polymorphisms and their functionality. Cytokine Growth Factor Rev 20:
43–59.
47. Ljungman P, Bellander T, Nyberg F, Lampa E, Jacquemin B, et al. (2009) DNA
variants, plasma levels and variability of interleukin-6 in myocardial infarction
survivors: results from the AIRGENE study. Thromb Res 124: 57–64.
48. Giachelia M, Voso MT, Tisi MC, Martini M, Bozzoli V, et al. (2012)
Interleukin-6 plasma levels are modulated by a polymorphism in the NF-
kappaB1 gene and are associated with outcome following rituximab-combined
chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. Leuk Lymphoma
53: 411–416.
The Functional TLR-9 Promoter Polymorphism in ESRD
PLOS ONE | www.plosone.org 7 March 2013 | Volume 8 | Issue 3 | e58444
